Showing 101-110 of 5127 results for "".
- Global Integral Beauty Conference Marks Fifth Anniversary With Expanded International Programhttps://practicaldermatology.com/news/global-integral-beauty-conference-marks-fifth-anniversary-with-expanded-international-program/2487545/Global Integral Beauty (GIB) has announced that its 5th Global Integral Beauty Conference will be held on October 17, 2026, at the New York Marriott Marquis in New York, New York. Now entering its fifth year, the conference s
- Maternal Type 2 Diabetes Not Linked to Reduced AD Risk in Children: Studyhttps://practicaldermatology.com/news/maternal-type-2-diabetes-not-linked-to-reduced-ad-risk-in-children-study/2487400/New research suggests maternal type 2 diabetes mellitus (T2DM) does not independently influence the risk of atopic dermatitis (AD) in children. Researchers for a retrospective cohort study analyzed electronic medical and birth records from Clalit Health Services in Israel (n = 314,224 moth
- Review: GLP-1 Receptor Agonists May Benefit Both Psoriasis and Metabolic Diseasehttps://practicaldermatology.com/news/review-glp-1-receptor-agonists-may-benefit-both-psoriasis-and-metabolic-disease/2487389/Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer additional benefits for patients with psoriasis, according to a new review and primer from the National Psoriasis Foundation Medical Board. The authors noted GLP-1 RAs have been associated with reductions in Psoriasis Area and
- Avapritinib Shows Dermatologic Benefits in Indolent Systemic Mastocytosishttps://practicaldermatology.com/news/avapritinib-shows-dermatologic-benefits-in-indolent-systemic-mastocytosis/2487380/Treatment with avapritinib led to substantial improvements in cutaneous disease manifestations among patients with indolent systemic mastocytosis (ISM), according to results from the phase 2 PIONEER study. Investigators for
- PanOxyl Portfolio Highlights Accessibility and Long-Term Acne Management During Virtual Desksidehttps://practicaldermatology.com/news/panoxyl-portfolio-highlights-accessibility-and-long-term-acne-management-during-virtual-deskside/2487257/Acne management requires a broader approach than simply targeting active breakouts, according to speakers during a virtual media deskside hosted by Revance. The discussion focused on over-the-counter acne management strategies with the PanOxyl brand as well as procedural options for acne scar tre
- Study: Hair Care Regimen May Enhance Minoxidil Response in Women With Hair Losshttps://practicaldermatology.com/news/seen-study-suggests-hair-care-regimen-may-enhance-minoxidil-response-in-women-with-hair-loss/2487130/SEEN Hair Care presented new clinical findings at the 2026 Music City Symposium for Cosmetic Advances and Laser Education (SCALE), suggesting that a non-comedogenic, non-irritating hair care regimen may improve outcomes with topical minoxidil 5% foam in women with
- Iron Oxides in Tinted Sunscreens May Improve Hyperpigmentation Protection: Studyhttps://practicaldermatology.com/news/iron-oxides-in-tinted-sunscreens-may-improve-hyperpigmentation-protection-study/2487035/A literature review and product analysis published in the Journal of Drugs in Dermatology highlighted growing evidence supporting the use of iron oxides in tinted sunscreens for managing hyperpigmentation, while also identif
- BPO Not Linked with Higher Malignancy Risk: Meta-analysishttps://practicaldermatology.com/news/bpo-not-linked-with-higher-malignancy-risk-meta-analysis/2486846/Benzoyl peroxide (BPO) use for acne vulgaris was not significantly associated with increased malignancy risk in a systematic review and meta-analysis of more than 4 million patients, accoriding to results from a new meta-analysis.
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitishttps://practicaldermatology.com/news/reduced-dose-tralokinumab-maintains-symptom-control-for-up-to-1-year-in-atopic-dermatitis/2485613/Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April